Realcan Pharmaceutical Group Co.Ltd(002589)
Independent directors’ opinions on relevant matters of the 19th meeting of the Fourth Board of directors
Prior approval of
As an independent director of Realcan Pharmaceutical Group Co.Ltd(002589) (hereinafter referred to as “the company”), in accordance with the stock listing rules of Shenzhen Stock Exchange (revised in 2022) and the guiding opinions on the establishment of independent director system in listed companies In line with the principle of prudence and the position of independent judgment, in accordance with the relevant provisions of relevant laws and regulations such as the guidelines for self-discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board and the relevant provisions of the company’s working system for independent directors, we express the following prior approval opinions on the relevant matters considered at the 19th meeting of the Fourth Board of directors of the company:
After review, we believe that the acquisition of part of the equity and related party transactions of Tianjin guohuida Health Technology Co., Ltd. complies with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange (revised in 2022), the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board, and the articles of association, The reasons for the transaction between the two parties of the related party transaction are reasonable and sufficient, the pricing principles and methods of the related party transaction are appropriate and reasonable, and the related matters of the related party transaction will perform the necessary internal decision-making procedures of the related party transaction. The related party transaction does not violate the principles of openness, fairness and impartiality, and does not harm the interests of the company and its shareholders, especially the minority shareholders. Therefore, we agree to submit this matter to the 19th meeting of the Fourth Board of directors of the company for deliberation.
Related directors Mr. Han Xu, Ms. Zhang Renhua, Mr. Han Chunlin and Mr. Yang Bo need to avoid voting when considering the proposal.
(there is no text on this page, which is the signature page of Realcan Pharmaceutical Group Co.Ltd(002589) independent directors’ prior approval opinions on matters related to the 19th meeting of the Fourth Board of directors) independent directors:
Wu binliu Xijun Yu Jianqing
February 17, 2022
